Replies to post #88611 on Anavex Life Sciences Corp (AVXL)

[gburgin]

I've seen the Greek patent and it had a priority date sometime in Feb of 1996 so it's original 20 year term expired early last year. The Greeks allow for a 5 year extension which I assume Anavex filed for so that would mean about 4 more years, but that protection is only in Greece.

Re Greek patents.
"The total duration of a patent can be prolonged for up to 5 years in the case of medicinal or plant protection product inventions for which a valid
Supplementary Protection Certificate application is filed."

[LakeshoreLeo1953]

Other than US Patent granted for "A3-71" the Greek purchases
are best summarized below:

Patent No.
1002616/Greece February 21, 1996/
February 20, 1997/
February 20, 2017 Invention related to the synthesis and the method of synthesis of molecules of a novel formula. This method is to be applied for the obtention of anticonvulsant, antidepressant and nootropic pharmaceuticals.
Patent No.
1004208/Greece
Filing October 15, 2001/
Issued April 4, 2003/
Expiration April 4, 2023
Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel ligands, with synergic sigma/muscarinic (neuroactivating) and sigma/sodium channel (neuroprotective) components, as prototypical activating – neuroprotectors and neuroregenerative drugs
Patent No.
1004868/Greece
Filing April 22, 2003/
Issued April 26, 2005/
Expiration April 26, 2025
Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel ligands, ortho-and allo-sterically operating, as prototypical neuromodulating and neuroregenerative drugs
Patent Application No.
20070100020/
Greece
Filing January 17, 2007
Issued April 7, 2008
Expiration January 18, 2027
New sigma (œ) receptor ligands with anti-apoptotic and/or pro- apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action